Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment

Chieh-Liang Huang1,2†, Yao-Chang Chiang3†, Wei-Chun Chang2,4†, Yu-Ting Su2,4, Juan-Cheng Yang2, Wei-Chung Cheng2,4, Hsien-Yuan Lane2,4, Ing-Kang Ho2,4 and Wen-Lung Ma2,4,5*

1 Tsaotun Psychiatric Center, Ministry of Health and Welfare, Taichung, Taiwan, 2 Sex Hormone Research Center, Center for Drug Abuse and Addiction, Chinese Medicine Research and Development Center, Department of Psychiatry, Department of OBS & GYN, China Medical University Hospital, Taichung, Taiwan, 3 Department of Nursing, Division of Basic Medical Sciences, Chang Gung University of Science and Technology, ChiaYi County, Taiwan, 4 Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University, Taichung, Taiwan, 5 Department of Nursing, Asia University, Taichung, Taiwan

INTRODUCTION

The use of illicit opioids remains an ongoing issue for both individuals and society at large (1). Individuals who develop opioid dependency often experience personal or social problems and often engage in opioid abuse. Opioid abuse patients present with behavioral changes, such as social withdrawal (2); increased risk of contracting human immunodeficiency virus (HIV); and greater
susceptibility to other opportunistic infections, such as hepatitis C and tuberculosis (TB) (3). In addition, individuals who abuse opiates exhibit higher rates of other infections (4); medical and psychiatric comorbidities (5); polysubstance consumption (5); and criminal behaviors, and an increase in opioid abuse has resulted in a surge in opioid-related deaths (6).

Methadone maintenance treatment (MMT) consists of the administration of methadone over a prolonged period of time to treat an individual addicted to opioids, such as heroin. MMT is typically used to treat individuals who experience relapse following typical detoxification regimens or admission to a substance abuse treatment facility that requires complete abstinence (7). MMT facilitates “social rehabilitation” by allowing people with addiction to avoid the uncomfortable withdrawal symptoms associated with complete abstinence. MMT has been used to treat opioid abuse patients for decades and has long served as the standard treatment for opioid dependence. However, MMT is associated with complications, including differential efficacies, and some patients experience difficulty during the transition from MMT to abstinence (8).

Appropriate dosing that aims to prevent the occurrence of withdrawal symptoms is a key component of the MMT strategy and is typically divided into three phases. When a patient first visits a treatment clinic, their craving for opiates is evaluated, and the initial dosage is determined and administered accordingly. The physician can then increase the dosage if the cravings are not mitigated by the initial dose. This stage is referred to as the “tolerance phase”, and during this period, the maximal methadone dose (MAX) is typically administered. Once a good balance between dosing and craving is achieved, the physician will gradually reduce the dosage to push the boundary at which the craving reoccurs. This stage of treatment is called the “tapering phase”, during which a steady-state (SS) methadone dosage is established. During this phase, social and mental support are typically provided to reduce the probability that the patient will seek the acquisition of street drugs. Finally, the physician will discontinue methadone dosing. This stage of MMT is called the “abstinence phase” and requires continued social and mental support. The evaluation of MMT outcomes is based on the degree to which opiate-addicted patients can be successfully maintained in treatment programs, which contribute to the prevention of potential social impacts from crime and other addiction-related behaviors. However, significant numbers of opiate abusers who undergo MMT discontinue their treatment programs due to insufficient dosage, often in favor of the acquisition of street drugs (9, 10). Unfortunately, methadone overdose can be fatal (11), requiring strict constraints on dosing during the tolerance phase.

Studies published in recent years have reported sex-associated disparities in the efficacy and complication rates associated with MMT, although the results have varied across different geographic regions. Therefore, in the present report, we aimed to summarize the current knowledge regarding these issues and, through preliminary tests, provide important perspectives regarding potential treatment strategies for addressing them.

Sex Disparities in MMT Efficacy

A sex disparity in the responses to MMT regimens has been reported, with women experiencing more psychological symptoms than men (12). In 2015, Bawor et al. (6) published a meta-analysis reviewing 22 clinical studies involving a total of almost ten thousand patients to evaluate the therapeutic outcomes of MMT. They found that men and women differed significantly in terms of alcohol use, amphetamine use, legal involvement, and employment while receiving MMT treatment. Sex differences were also prominent in terms of polysubstance use. Meanwhile, a national cohort study of ten thousand patients (the VEdette study) also examined sex-related differences among MMT recipients (13). In that study, the women were younger and more likely to be married, divorced, or widowed than the men, and the women also had higher rates of unemployment despite being better educated on average. The men were reported to use sedatives more frequently and presented with higher rates of psychiatric comorbidities (such as depression, self-injury attempts, and suicide attempts). High doses of methadone and the use of methadone in combination with psychotherapy improved treatment retention for both men and women. Therefore, the VEdette study results suggested that a sex-sensitive approach should be applied to improve MMT outcomes. Consistent with the VEdette study, another national cohort study (14) also found that women receiving MMT had high rates of physical and psychological problems, including inherited psychiatric illnesses, and often began using opioids following a physician’s prescription. By contrast, a study by Leone et al. (12) found that MMT was significantly associated with higher psychological symptom scores in men compared with women. Wang et al. (15) reported that the levels of depression among women receiving MMT decreased faster than those in men receiving MMT.

When examining sex-specific differences in MMT outcomes, women are reported to have higher odds of discontinuing MMT to seek illicit opioids than men (16, 17). This discrepancy could be associated with pharmacodynamic differences because the methadone concentration-to-dose ratio (CDR) has been reported to be significantly lower among women than men (18). One study indicated that the MMT discontinuation rate could partially be attributed to MMT complications associated with prolonged QT intervals (19) (the QT interval is the time from the beginning of the QRS complex in an electrocardiograph, representing ventricular depolarization, to the end of the T wave, resulting from ventricular repolarization), although the results of another study did not support this theory (20). However, prolonged QT intervals could be associated with differences in the serum levels of sex hormones (21). Yee et al. (21) reported that men receiving MMT had testosterone levels lower than the reference range for male patients not receiving MMT. Interestingly, altered testosterone levels appear to be unrelated to prolactin levels (21), which suggests the involvement of steroidogenic cytochrome enzymes in the associated process. Kringen et al. (22) reported that the feminizing cytochrome gene family CYP2B6, which is regulated by estrogen signals, could be involved in regulating the CDR in MMT patients.
The Impacts of Estrogen Signaling on MMT Efficacy
As early as the 1970s, a report described the complication of amenorrhea among women treated with methadone, which was associated with the secretion of gonadotropins from the hypothalamus (23). Therefore, methadone metabolism was suspected to be related to sex hormone production. For example, studies showed that the placental aromatase CYP19 mediated methadone metabolism and that methadone suppressed the aromatization of testosterone to estrone (24, 25). The suppression of estrogen production might represent a long-term effect of methadone rather than an acute response (26). These studies strongly indicated that MMT could alter sex hormone production through CYP19 enzymes. In 2010, Lu et al. (27) discovered direct evidence showing that methadone is metabolized by CYP19 and may inhibit CYP19 in vivo.

Sex-related differences in methadone metabolites are prominent in the literature. Chalabianloo et al. (18) found that the CDR was significantly reduced among women compared with men, particularly in those women concurrently using CYP inducers and high doses of CYP3A4 inhibitors. Several lines of evidence suggest that CYP2B6, one of the feminizing CYPs, increases the drug clearance of methadone in pregnant women, and pregnancy is characterized by elevated estradiol (E2) levels (28). In addition, CYP2B6 can be activated by xenotropic agents, including the synthetic opioids pethidine and methadone, through the activation of the constitutive androstane receptor and pregnane X receptor in the liver (29).

In a recent study, Chiang et al. (30) showed that high estrogen levels were correlated with high MMT doses. Chiang et al. also showed that the expression of the ER-regulating CYP2B6 single-nucleotide polymorphism (SNP) was associated with MMT dosing. They replicated the phenotype observed in mice and found that the ablation of estrogen levels by ovariectomy in female mice suppressed methadone metabolism. By contrast, the implantation of E2 in male mice facilitated methadone metabolism. The manipulation of E2 levels also altered the addictive behaviors among mice addicted to methadone. The conditioned place preference (CPP) test, which measures retention time to evaluate the opioid craving status, was used to demonstrate that increased estrogen levels increased the retention time of methadone in both sexes.

Due to the existing complications associated with MMT, sex-related differences in efficacy, and interference of CYP19 in MMT efficacy, Chiang et al. proposed the potential of targeting estrogen receptor (ER) signaling to improve MMT efficacy. Therefore, we aimed to re-examine the effects of estrogen-ER signaling in MMT.

METHODOLOGY

Study Subjects
All experimental procedures for human studies were approved by the China Medical University Hospital (CMUH) Institutional review board (DMR94-IRB-007), and informed consent was obtained from each subject. The cohort consisted of 326 heroin abusers (age range: 20–70 years) recruited from January 2010–December 2013 from among psychiatric outpatients treated by CMUH in Taichung, Taiwan. In addition, each patient received methadone therapy for at least 6 months and maintained an unchanged methadone dosage for at least 4 weeks prior to recruitment. Subjects who received other medications that might affect methadone metabolism or who had any Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) Axis I or II psychiatric disorders were excluded from this study. At the time of enrollment, all subjects were asked to complete a questionnaire that included demographic data and a survey of heroin addictive behavior.

Generation and Housing of ERα and ERβ Knockout Mice
All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the Ministry of Science and Technology and were conducted with approval from China Medical University (approval number #103-36-N). The ERα-knockout (KO) mice (ActbCre-ERαloxP/loxP) and ERβ-KO mice (ERβfl/fl) used in our study were kindly provided by Prof. Shuyuan Yeh and Prof. Chawnshang Chang, respectively, at the University of Rochester, NY, USA (31, 32). To generate ERα-KO mice (33, 34), transgenic ERαloxP/loxP mice were crossed with ActbCre (β-actin promoter–driven Cre recombinase) transgenic mice to generate male ERα-KO (ERα−/−) mice. The control mice were ERαloxP/loxP without ActbCre. ERβ-KO (ERβ−/−) mice were generated by crossing heterozygote (ERβ+/−) mice and littermate wild-type (ERβ+/+) mice. PCR was used to identify the mouse genotypes from DNA obtained from tail skin treated overnight with cell lysis buffer containing 0.5 mg/ml proteinase K (Sigma, P2308). All wild-type vs. ERα−/− or ERβ−/− mice used in these studies were 2–4 months old and male. All protocols related to animal use and treatment were evaluated and approved by the Animal Care and Use Committee of China Medical University, and all animals were treated in accordance with National Laboratory for Experimental Animals guidelines.

E2/Tamoxifen Injection Protocol
The E2/tamoxifen (TMX) injection procedure was performed as previously described (35). In brief, E2 (Sigma-Aldrich) or TMX (Sigma-Aldrich) were dissolved in sesame oil/ethanol vehicle (9:1, v/v). Each mouse was injected subcutaneously (s.c.) with either 0.01 mL vehicle or vehicle containing 20 µg E2 or 100 µg TMX for 4 consecutive weeks, 3 times/week.

Tail-Flick Assay
The tail-flick test was performed in mice using a modified version of the method described by Dai et al. (36) The tail-flick latency was defined by the time (in seconds) for the animal to withdraw its tail from a heat source (bulb, 8 V/50 W, OSRAM, Germany), and was measured using a semi-automated machine (Columbus Instruments, Columbus, OH, USA). The infrared intensity of the tail-flick machine was set at 8, which produced a baseline tail-flick latency of 2–3 seconds, and the cutoff time was
set to 10 seconds to prevent tissue damage. The mice were adapted to the restrainer for 5 min prior to performing the tail-flick test. To measure the analgesic effects of opioid agonists, the animals were subjected to the tail-flick procedure once per day to minimize learning effects. All of the experimental animals were randomly assigned from different cages to ensure a general effect in the population. The antinociceptive effects were presented as the area under the time-response curve (AUC = latency × time).

**SNP Variant Selection**

All SNPs identified in methadone metabolism–related enzymes [opioid-related nociceptin receptor 1 (OPRL-1) and CYP2B6] were analyzed (using the UCSC genome browser; http://genome.ucsc.edu). The putative estrogen response element (ERE) areas were identified by comparing the results predicted by the TFSEARCH website (http://www.cbrc.jp/research/db/TFSEARCH.html) and the PreMod (37) database (http://genomequebec.mcgill.ca/PreMod/). The genotypes of ERE-SNP alignment scores were determined using TheBEST (The Binding Element Searching Tool; http://thebest.binfo.ncku.edu.tw/thebest/) algorithm.

**DNA Isolation and Genotyping**

Genomic DNA was extracted from 8–10 ml peripheral whole-blood samples using the MasterPure™ DNA Purification Kit for Blood Version II (Epicentre, Madison, WI, USA). DNA specimens were dissolved in Tris-EDTA (TE) buffer and stored at −20°C until PCR. All of the ERE-SNPs (Table 1) were determined using Sequenom iPlex MALDI-TOF (matrix-assisted laser desorption ionization-time of flight; Sequenom Inc., San Diego, CA, USA), according to the manufacturer’s protocol.

**Chemicals, Reagents, and Cell Culture**

Methadone hydrochloride (USP, USA) was dissolved in distilled water and administered s.c. in a volume of 1.0 ml/kg body weight. E2 and TMX were obtained from Sigma-Aldrich (CA, USA).

**Enantiomeric EDDP/Methadone Detection by LC–MS/MS**

The sample preparation and measurement of the R/S-forms of enantiomeric methadone or 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), a methadone metabolite, were performed as previously described, with modifications (38, 39). In brief, each sample was prepared as follows: standard (R, S)–methadone or EDDP was purchased from Sigma-Aldrich, CA, USA. For (R,S)–methadone and EDDP, the calibration curve points were: 0, 100, 250, 500, 1000, and 2000 ng/ml. Liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis was performed on an API 2000 LC–MS/MS system (AB Sciex, Ontario, Canada), interfaced with a high-performance liquid chromatography (HPLC) pump equipped with an autosampler (1100 series, Agilent, Waldbronn, Germany). A 50 µl volume of plasma sample was mixed with 100 µl of internal standard (EDDP-D3) and filtered for use. After 2 minutes of vortexing, the sample was centrifuged at 15,000 x g for 15 min, and the supernatant was applied for LC–MS/MS analysis. A Chiralcel OD-R column (250 x 4.6 mm, 5-µm particle size, Daicel Chemical Industries Ltd., Japan) was used, and the isocratic mobile phase system was run under a flow rate of 0.5 mL/min (phase A: 0.1% formic acid in acetonitrile, phase B: 10 mM ammonium acetate). The Q1/Q3 of EDDP was 278.3/234.3, whereas that of methadone was 310.1/265.6, and that of EDDP-D9 was 319.3/268.3.

**E2 Detection by ECLIA Assay**

Electrochemiluminescent immunoassay (ECLIA) was used for the quantitative determination of estrogen levels in mouse serum on a Roche Elecsys 2010 instrument (Roche, Basel, Switzerland), according to the manufacturer’s instructions. The chemiluminescence reaction for the detection of the reaction complex was initiated by applying a voltage to the sample solution, resulting in a precisely controlled reaction. Serum E2 values are provided as pg/ml (pg/ml × 3.67 = pmol/l). The functional sensitivity of the E2 assay was 5 pg/ml (18.4 pmol/l), with a total analytical sensitivity of <5%.

**Statistical Analysis**

Student’s t-test was used to assess differences between luciferase activity across genotypes. In addition, we also employed Student’s t-test to compare the different methadone doses and sex hormone levels in patients between sexes during the trials. Correlations were analyzed between sex hormone levels and the EDDP/methadone ratios. The pharmacokinetic data were analyzed with a two-way analysis of variance (ANOVA). The significance level was set to a two-sided P < 0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, North Carolina, USA).

**RESULT**

**Estrogen Receptors Directly Modulate Methadone Metabolism to Alter MMT Efficacy**

To correlate estrogen levels with the outcomes of MMT, we measured the E2 levels of patients undergoing an MMT program in a cohort study. As shown in Table 1, sex, BMI, and HIV infection status appeared to have little effect on the MMT dosing level among the cohort, although age did have an effect, with younger ages correlated with higher MAX MMT dosages. We also measured the E2 levels of the patients in this cohort and found that they were associated with the MAX dose during the tolerance phase, the SS dose at the onset of the tapering phase, and the previous term of MAX dosing (pMAX). As shown in Figure 1A, higher E2 levels (cutoff 20 ng/dl) were associated with higher MAX and pMAX values.

Using the well-known ERE (Figure 1B), SNP sequence alignments were performed to determine which genes are correlated with the opioid response and opioid metabolism. We identified four SNPs with high prediction scores, including the three SNPs in OPRL1 (rs7271530, rs6010717, and rs2229205) and one SNP in CYP2B6 (rs16974799; Figure 1C). As shown in Table 1, these SNPs were preferentially correlated with the MMT MAX value. Among the OPRL1 SNPs, rs7271530 (T-variant;
dominant inheritance) and rs6010717 (G-variant; dominant inheritance) were associated with high MMT MAX values. In addition, the CYP2B6 SNP rs16974799 (C-variant; recessive inheritance) was also associated with a high MMT MAX value. These data indicated the potential for the direct regulation of estrogen/ER signaling to affect the MMT response.

To verify that ERs (ERα and ERβ) are involved in the methadone response, we used ERα and ERβ KO mice to test the acute effects of methadone. As shown in Figure 2A, ERα KO increased E2 levels, and the tail-flick test showed a prolonged analgesic response to methadone in ERα KO mice compared with wild-type mice (Figure 2B). By contrast, the ERβ KO mice did not exhibit altered E2 levels (Figure 2C), although they also exhibited a prolonged analgesic response to methadone compared with wild-type mice (Figure 2D). These data provide direct evidence that estrogen signaling decreased the methadone response through both ERα and ERβ in mice.

### The Potential Strategies for Targeting Estrogen Signaling in MMT

Two major estrogenic ablation therapies are currently used to treat estrogen-sensitive breast cancer. One consists of inhibiting the ER function using with SERMs, whereas the other consists of reducing estrogen production through the use of aromatase inhibitors (AIs) to inhibit enzymatic activity. The following section will discuss the potential use of anti-estrogenic agents, such as SERMs or AIs, as an add-on therapy during MMT.

The pharmacological action of AIs involves the inhibition of aromatase enzymatic activity to suppress estrogen signaling by inhibiting E2 production in the ovary/liver (40) and adipose tissues (41). AIs have been demonstrated to influence female reproductive systems. For example, Wu et al. (42) conducted a randomized trial using the AI anastrozole and found that it was associated with high pregnancy rates, although treatment was also associated with fewer ovulatory follicles compared with treatment by clomiphene citrate. In another study, Tabatabaie et al. (43) used the AI letrozole combined with medroxyprogesterone acetate to treat endometrial hyperplasia and found that it exhibited good performance for preserving fertility in young women. In a recent study, AIs were shown to be useful for ovarian stimulation prior to oocyte/embryo cryopreservation in estrogen-sensitive cancer patients (44).

The pharmacological action of SERMs involves the suppression of estrogenic signaling through the inhibition of ER function by preventing the estrogen-induced transactivation

**TABLE 1 | Demograph of MMT cohort in association of SNP and MMT dosing.**

| Variable | <50 mg (87 patients) | 51–100 mg (163 patients) | >100 mg (45 patients) | p-value |
|----------|----------------------|--------------------------|----------------------|---------|
| **Sex**  | Male                 | 69 (29.4%)               | 133 (56.6%)          | 33 (14.0%) | 0.3446 |
|          | Female               | 18 (29.5%)               | 30 (49.2%)           | 13 (21.3%) |         |
| **Age**  | 41.0±7.3             | 41.9±7.4                 | 38.3±7.0             | 0.0158   |
| **BMI**  | 22.8±3.1             | 22.7±2.7                 | 22.6±2.4             |          |
| **HIV**  | HIV (-)              | 5/61 (100%)              | 150/154 (97.4%)      | 64/66 (96.97%) | 0.9176 |
|          | HIV (+)              | 0/51 (0%)                | 5 (83.3%)            | 1 (16.7%) |
| **OPRL-1: rs7271530** | TT                   | 21 (26.6%)               | 55 (36.7%)           | 13 (32.5%) | 0.0747 |
|          | CC                   | 14 (17.7%)               | 17 (11.3%)           | 11 (27.5%) |         |
|          | CT                   | 44 (55.7%)               | 78 (52.0%)           | 16 (40.0%) |         |
| **Dominant** | TT+CT               | 65 (82.3%)               | 133 (88.7%)          | 29(72.5%) | 0.0361 |
|          | CC                   | 14 (17.7%)               | 17 (11.3%)           | 11(27.5%) |         |
| **OPRL-1: rs6010717** | CT+CC               | 58 (73.4%)               | 95 (63.3%)           | 27 (67.5%) | 0.3036 |
|          | TT                   | 21 (26.6%)               | 55 (36.7%)           | 13 (32.5%) |         |
| **Dominant** | GG+CG               | 66 (84.6%)               | 141 (94.0%)          | 36(92.3%) | 0.0361 |
|          | CC                   | 14 (17.7%)               | 17 (11.3%)           | 11(27.5%) |         |
| **OPRL: rs2229205** | GG+CC               | 49 (62.8%)               | 80 (53.3%)           | 19 (48.7%) | 0.3036 |
|          | CC                   | 29 (37.2%)               | 70 (46.7%)           | 20 (51.3%) |         |
| **Dominant** | CC+CT               | 70 (100%)                | 148 (97.4%)          | 37 (92.5%) | 0.0513 |
|          | TT                   | 0 (0.0%)                 | 4 (2.6%)             | 3 (7.5%) |         |
| **OPRL-1: rs6197477** | CC+CT               | 79 (100%)                | 148 (97.4%)          | 37 (92.5%) | 0.0513 |
|          | TT                   | 0 (0.0%)                 | 4 (2.6%)             | 3 (7.5%) |         |
| **CYP2B6: rs16974799** | CC                  | 41 (51.9%)               | 101 (66.5%)          | 31(77.5%) | 0.0374 |
|          | TT                   | 33 (41.8%)               | 4 (2.6%)             | 0 (0.0%) |         |
|          | CT                   | 5 (6.3%)                 | 47 (30.9%)           | 9(22.5%) | 0.1477 |
| **Dominant** | CC+TT               | 74 (93.7%)               | 148 (97.4%)          | 40 (100%) |         |
|          | TT                   | 5 (6.3%)                 | 4 (2.6%)             | 0 (0.0%) |         |
| **Recessive** | CT+TT               | 38 (48.1%)               | 51 (33.6%)           | 9(22.5%) | 0.0138 |
|          | CC                   | 41 (51.9%)               | 101 (66.5%)          | 31(77.5%) |         |

Bold value indicating a significance difference between groups.
FIGURE 1 | E2 effects on MMT dosing. (A) The MMT dosing in patients with low (<20 ng/dL) or high (≥20 ng/dL) estradiol (E2) levels. MAX (red-colored dots) indicates the maximal dosing of methadone during the MMT regimen; SS (blue-colored dots) indicates the steady-state dosing of methadone during the MMT regimen; and pMAX (green-colored dots) indicates the previous MAX of patients receiving a previous term of MMT. (B) The classical ERE sequences and scoring standard for predicting a potential SNP-ERE. (C) The locations of the four SNPs on the putative ERE. The OPRL1 SNPs (rs7271530, rs6010717, and rs2229205) and CYP2B6 SNP (rs16974799) sequences are shown, and red-dashed rectangles depict the putative ERE region and nearby sequences. The * indicates a significant p-value < 0.05 obtained using Student’s t-test.
of ERs. However, the use of the SERM TMX in female patients has also been associated with complications. For example, as early as 1998, Mishell et al. (45) reported that TMX administration followed by intravaginal misoprostol could be used to induce abortion in pregnancies as late as 56 days of gestational age. SERMs, including clomiphene citrate and TMX, have also been used as the first-line treatment of choice for anovulation (46). Shandley et al. (47) and Wright et al. (48) also reported that women treated with TMX were more likely to experience gynecological complications than those treated with AIs.

From these findings, AIs might appear to be a better choice for use with MMT regimens. However, the effects of these additions in male patients, which constitute the majority of MMT patients, must also be considered. In addition, a recent report indicated that AIs could increase the chances of developing insulin insensitivity (49), which represents another potential factor that should be considered prior to using AIs in MMT.

Some reports have suggested that the use of AIs in male patients could lead to increased sexual activity and increased erectile ability (50, 51). In addition, the use of AIs could also increase the chances of pregnancy in females, compared with the use of SERMs (43).

Chiang et al. (30) tested estrogen signal targeting using SERMs in MMT by adding the SERM TTX to the tolerance, tapering, and abstinence phases of MMT in a mouse model. The results showed excellent tolerance behavior, and the addition of TMX to MMT also enhanced the CPP retention time, indicating that TMX has the potential to relieve stress-induced cravings for opioids during the tolerance phase of MMT programs, which could prevent the chances of a methadone overdose. More strikingly, the addition of TMX to the tapering and abstinence phases rapidly reduced the CPP retention time, which indicates that the addition of TMX to the MMT protocol was able to reduce drug-seeking behavior even as the methadone dose was reduced.
Although the study by Chiang et al. showed that one phenotype observed in response to targeting ERs with TMX was beneficial for MMT program efficacy, whether TMX exerts pharmacological effects on methadone metabolism remains unclear. Therefore, we conducted a longer-term treatment consisting of methadone with and without TMX to observe the levels of racemic methadone (R/S-methadone) and its metabolite R/S-EDDP (2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidin). We used a rat model that was injected with TMX for 6 days, followed by methadone injection on day 7, and the methadone/EDDP concentrations in the serum were determined (Figure 3A). Different groups of animals were injected with placebo, low (5 mg/kg), and high (10 mg/kg) doses of TMX, after which the TMX concentration in the serum was measured. The results obtained showed that the serum concentrations of TMX were differentially elevated in response to the various injection doses (Figure 3B). The three groups of rats were intraperitoneally injected with methadone, and racemic R/S-methadone and its metabolite R/S-EDDP were monitored for 4 h. As shown in Figure 3C, the serum R-methadone retention times were prolonged, and the Cmax (maximal/peak serum concentration) values were significantly increased. For R-EDDP (Figure 3D), the retention time was prolonged, but the Cmax values for R-EDDP remained unchanged. By contrast, S-methadone retention times were prolonged, and the associated Cmax values were dramatically increased (Figures 3E, F). In addition, the S-EDDP retention time was prolonged, but the Cmax values for S-EDDP remained unchanged. R-methadone is the pharmacologically active racemate, whereas S-methadone is the racemate associated with complications (52, 53); therefore, TMX may not be the ideal SERM for use as an add-on to MMT. The mechanism underlying the superior...
suppressive effect on S-methadone metabolism may be associated with the TMX-mediated inhibition of CYP2B6 being more effective in experimental rodents compared with the inhibition of human CYP2C19 (30). However, the ability to utilize TMX to suppress ER function and prolong methadone metabolism was confirmed by this study.

In methadone metabolism, S-racemate is majorly metabolized by CYP2B6, whereas the R-racemate is metabolized by CYP2C19 (54, 55). In addition, CYP3A4 is a potent methadone-metabolizing enzyme without an indicated preference for either racemate (56). Several clinically available SERMs can be tested as add-on anti-ER agents in MMT. Raloxifene is a SERMs that has been reported to suppress CYP3A4 and CYP2C19 (57). Raloxifene has been reported to inactivate CYP3A4 kinetics with K(I) and k(inact) values of 0.81 µM and 0.20 min⁻¹, respectively (57), by forming a homodimer within the CYP3A4 protein (58, 59). Other SERMs, such as ospemifene (60, 61) (a non-steroidal SERM) and LY2066948 (62) (which was developed by Eli Lilly to treat uterine fibroid myomas), could be also be considered for add-on MMT therapy given their excellent interactions with CYP3A4 and CYP2C19. Therefore, raloxifene, ospemifene, and LY2066948 could potentially be tested as add-on agents in MMT for opiate abuse patients. As indicated in Figure 4, the selective antagonism of R/S-methadone racemates that can be achieved by suppressing CYP2C19, CYP2B6, or CYP3A4 with SERMs might represent an excellent strategy for the future development of new MMT regimens.

CONCLUSION

In this perspective article, we reviewed the roles of sex disparities in MMT recipients and tested the possibility of using a SERM, specifically TMX, to affect methadone metabolism. Our report indicated that the addition of an effective SERM to MMT regimens might exert beneficial effects by extending methadone metabolism, as the addition of TMX increased the Cmax in a rat model. Although the use of TMX led to more robust increases in S-methadone, which is associated with complications, future testing with other SERMs would be of great interest.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

All of the experimental procedures of the human studies were approved by the China Medical University Hospital (CMUH) Institutional review board (DMR94-IRB-007), and informed consent was obtained from each subject. The patients/participants provided their written informed consent to participate in this study. All protocols related to animal use and treatment were evaluated and approved by the Animal Care
and Use Committee of China Medical University, and all animals were treated in accordance with National Laboratory for Experimental Animals guidelines.

**AUTHOR CONTRIBUTIONS**

C-LH and W-CCha recruited patients, performed statistical analyses, and composed the manuscript. Y-CC and J-CY executed the animal experiments, performed statistical analyses, and edited the manuscript. Y-CC and J-CY initiated the study, interpreted the data, supported the entire project, and edited and approved the final manuscript. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Okie S. A Flood of Opioids, a Rising Tide of Deaths. *N Engl J Med* (2010) 363:1981–5. doi: 10.1056/NEJMp1011512
2. Marek RJ, Ben-Porath YS, Ashton K, Heinberg LJ. Impact of Using DSM-5 Criteria for Diagnosing Binge Eating Disorder in Bariatric Surgery Candidates: Change in Prevalence Rate, Demographic Characteristics, and Scores on the Minnesota Multiphasic Personality Inventory–2 Restructured Form (MMPI-2-R). *Int J Eat Disord* (2014) 47:553–7. doi: 10.1002/eat.22268
3. Dennis BB, Naji L, Bawor M, Bonner A, Bhalerao A, Worster A, et al. The Effectiveness of Opioid Substitution Treatments for Patients With Opioid Dependence: A Systematic Review and Multiple Treatment Comparison Protocol. *Syst Rev* (2014) 3:106. doi: 10.1186/2046-4053-3-105
4. Firestone Cruz M, Fischer B, Patra J, Kalousek K, Newton-Taylor B, Rehm J, et al. Prevalence and Associated Factors of Hepatitis C Infection (HCV) in a Multi-Site Canadian Population of Illicit Opioid and Other Drug Users (OPICAN). *Can J Public Health* (2007) 98:130–3. doi: 10.1007/BF03404324
5. Brooner RK, King VL, Kador M, Schmidt CW Jr, Bigelow GE. Psychiatric and Substance Use Comorbidity Among Treatment-Seeking Opioid Abusers. *Arch Gen Psychiatry* (1986) 43:71–80. doi: 10.1001/archpsyc.1986.01830130077015
6. Bawor M, Dennis BB, Bhalaria A, Plater C, Worster A, Varenbut M, et al. Sex Differences in Outcomes of Methadone Maintenance Treatment for Opioid Use Disorder: A Systematic Review and Meta-Analysis. *CMAJ Open* (2015) 3: E344–51. doi: 10.9778/cmao.20140089
7. Joseph H, Stanciiff S, Langrod J. Methadone Maintenance Treatment (MMT): a Review of Historical and Clinical Issues. *Mt Sinai J Med* (2000) 67:347–64.
8. Teoh Bing Fei J, Yee A, Habib MH, Danaee M. Effectiveness of Methadone Maintenance Therapy and Improvement in Quality of Life Following a Decade of Implementation. *J Subst Abuse Treat* (2016) 69:50–6. doi: 10.1016/j.jsat.2016.07.006
9. Yao T, Feng D, Pan MH, Cheng YP, Li CX, Wang J, et al. [Correlation Between Insufficient Methadone Dosage and Morphine Positive Urine on Drop Out of Treatment in Patients With Access to Methadone Maintenance Treatment]. *Zhonghua Liu Xing Bing Xue Za Zhi* (2017) 38:646–50.
10. Radzde E, Todadze K. Retention in Georgia Opioid Substitution Therapy Program and Associated Factors. *Harm Reduct J* (2016) 13:35. doi: 10.1186/s12954-016-0124-z
11. Brett J, Wylie CE, Raubenheimer J, Isbister GK, Buckley NA. The Relative Lethal Toxicity of Pharmaceutical and Illicit Substances: A 16-Year Study of the Greater Newcastle Hunter Area, Australia. *Br J Clin Pharmacol* (2019) 85:2098–107. doi: 10.1111/bcp.14019
12. Levine B, Di Nicola M, Moccia L, Pettorraso M, De Riso L, Nucara G, et al. Gender-Related Psychopathology in Opioid Use Disorder: Results From a Representative Sample of Italian Addiction Services. *Addict Behav* (2017) 71:107–10. doi: 10.1016/j.addbeh.2017.03.010
13. Vigna-Taglianti FD, Burroni P, Mathis F, Versino E, Beccaria F, Rotelli M, et al. Gender Differences in Heroin Addiction and Treatment: Results From the VEdeTTE Cohort. *Subst Use Misuse* (2016) 51:295–309. doi: 10.3109/10826068.2015.1108339
14. Bawor M, Dennis BB, Varenbut M, Daiter J, Marsh DC, Plater C, et al. Sex Differences in Substance Use, Health, and Social Functioning Among Opioid Users Receiving Methadone Treatment: A Multicenter Cohort Study. *Biol Sex Differ* (2015) 6:21. doi: 10.1186/s13293-015-0038-6
15. Wang SC, Chung RH, Kuo HW, Liu TH, Fang CP, Liu SC, et al. GRK5 Is Associated With the Regulation of Methadone Dosage in Heroin Dependence. *Int J Neuropsychopharmacol* (2018) 21:910–7. doi: 10.1093/ijnpypp066
16. Polenick CA, Cotton BP, Bryson WC, Birditt KS. Loneliness and Illicit Opioid Use Among Methadone Maintenance Treatment Patients. *Subst Use Misuse* (2019) 1–10. doi: 10.1080/10826068.2019.1628276
17. Li W, Wang Z, Liu Z. Factors Associated With Illicit Opioid Use in Methadone Maintenance Treatment Clients in 5 Provinces, China. *Environ Health Prev Med* (2016) 21:480–6. doi: 10.1007/s12199-016-0570-y
18. Chalabianlo F, Westin AA, Skogell E, Breamns JG, Spigset O. Methadone Serum Concentrations and Influencing Factors: A Naturalistic Observational Study. *Psychopharmacol (Berl)* (2019). doi: 10.1007/s00213-019-05277-1
19. Juba KM, Khademi TM, Hutchinson DJ, Brown JE. Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case-Control Study. *J Palliat Med* (2017) 20:722–8. doi: 10.1089/jpwm.2016.0411
20. Bart G, Wyman Z, Wang Q, Hodges JS, Karim R, Bart BA, et al. Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort. *J Addict Med* (2017) 11:489–93. doi: 10.1097/ADM.0000000000000353
21. Yee A, Loh HS, Danaee M, Riahi S, Ng CG, Sulaiman AH, et al. Plasma Testosterone and Sexual Function in Southeast Asian Men Receiving Methadone and Buprenorphine Maintenance Treatment. *J Sex Med* (2018) 15:159–66. doi: 10.1016/j.jsexmed.2017.12.004
22. Kringen MK, Chalabianlo F, Bernard JP, Breamns JG, Molden E, Hesseth G, et al. Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Therapy. *Ther Drug Monit* (2017) 39:550–5. doi: 10.1007/TFD.000000000000437
23. Santen FJ, Sofsky J, Blicik N, Lippert R. Mechanism of Action of Narcotics in Testosterone and Sexual Function in Southeast Asian Men Receiving Methadone Maintenance Treatment. *J Addict Med* (2018) 11:159–66. doi: 10.1016/j.jsexmed.2017.12.004
24. Zharikova OL, Deshmukh SV, Nanovskaya TN, Hankins GD, Ahmed MS, et al. Methadone Metabolism by Human Placenta. *Arch Biochem Biophys* (2004) 48:583–91. doi: 10.1016/j.abc.2004.04.011
25. Zharikova OL, Deshmukh SV, Nanovskaya TN, Hankins GD, Ahmed MS. The Effect of Methadone and Buprenorphine on Human Placental Aromatase. *Biochem Pharmacol* (2006) 71:1255–64. doi: 10.1016/j.bcp.2005.12.035
26. Zharikova OL, Deshmukh SV, Kumar M, Vargass R, Nanovskaya TN, Hankins GD, et al. The Effect of Opiates on the Activity of Human Placental
Equine Estrogen, Equilenin. *Chem Biol Interact* (2012) 196:1–10. doi: 10.1016/j.cbi.2012.01.004

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Huang, Chiang, Chang, Su, Yang, Cheng, Lane, Ho and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.